Sakar Healthcare Limited (NSE:SAKAR)

Market Cap	20.31B +191.2%
Revenue (ttm)	2.72B +43.8%
Net Income	360.98M +82.7%
EPS	16.20 +80.5%
Shares Out	22.25M
PE Ratio	56.33
Forward PE	39.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,888
Open	892.95
Previous Close	884.65
Day's Range	880.15 - 928.00
52-Week Range	317.00 - 980.00
Beta	0.45
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 24, 2026

About Sakar Healthcare

Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaestheti...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 342
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SAKAR

Financial Performance

In fiscal year 2026, Sakar Healthcare's revenue was 2.52 billion, an increase of 41.34% compared to the previous year's 1.78 billion. Earnings were 304.85 million, an increase of 74.18%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error